ReviewCancer management and research2026
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is the second leading cause of death worldwide, accounting for approximately 8.97 million deaths, and is projected to surpass ischemic heart disease as the leading cause by 2060. Lung, liver, and stomach cancers are the most lethal globally, while lung and breast cancers are the primary causes of cancer-related mortality in men and women, respectively. In response to this growing burden, there is an urgent need to explore novel therapeutic strategies beyond conventional treatments. Among these, plant-derived medicines offer promising alternatives. Aim: This review investigates the anti-cancer potential of Results: EA has demonstrated anti-cancer activity in breast, cervical, hepatocellular, oral, and colorectal cancer models. Mechanistically, EA induces apoptosis, arrests the cell cycle, modulates HER2/JNK and PI3K/AKT pathways, inhibits epithelial-mesenchymal transition, suppresses angiogenesis, and reduces oxidative stress. While preclinical data are encouraging, animal studies remain limited and clinical validation is lacking. Conclusion: EA shows promise as a therapeutic agent in cancer management. However, rigorous clinical trials are essential to confirm its safety and efficacy in humans. Future research should also explore its synergistic potential with conventional therapies and further elucidate its molecular mechanisms to support translational application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.